[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626437":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":15,"responsibleParty":37,"collaborators":7,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":7,"studyType":53,"phases":7,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":18,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Tata Memorial Hospital","OTHER_GOV",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":13,"email":14},"Supriya Chopra","CONTACT","02227405000","5113","supriyasastri@gmail.com",[16],{"facility":17,"status":18,"city":19,"state":20,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Tata Memorial Center","RECRUITING","Mumbai","Maharashtra","400012","India","IN",{"type":25,"coordinates":26},"Point",[27,28],72.88261,19.07283,{"lat":28,"lon":27},[31,34],{"name":32,"role":11,"phone":33,"phoneExt":13,"email":14},"Supriya sastri (Chopra), MD","022-68735000",{"name":35,"role":36,"phone":7,"phoneExt":7,"email":7},"Supriya Sastri (Chopra), MD","PRINCIPAL_INVESTIGATOR",{"type":36,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Supriya Sastri (chopra)","Professor","100626437","late-radiation-toxicities-in-cervical-and-endometrial-cancer-a-postoperative-imrtbrachytherapy-study-100626437",false,"NCT07435623","Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT\u002FBrachytherapy Study","Assessment of Late Gastrointestinal and Genitourinary Toxicities in Cervical and Endometrial Cancer Requiring Postoperative IMRT and\u002For Brachytherapy","Inclusion Criteria:\n\n* Patients more than 18 years of age at the time of diagnosis.\n* All patients with confirmed histological diagnosis of cervical or endometrial cancer.\n* Only those patients who have received adjuvant (chemo)radiotherapy with IMRT and\u002For brachytherapy at TMH\u002FACTREC will be included.\n* Patients whose follow up information available\n\nExclusion Criteria:\n\n* Patients with incomplete treatment details.\n* Patient having residual disease post-surgery.\n* Patient treated for post-operative recurrences.\n* Patient who lost to follow up.\n* Patients with Immunosuppressive disorder","FEMALE","18 Years","75 Years",{"count":51,"type":52},300,"ESTIMATED","OBSERVATIONAL","Cervical cancer is the 4th most common cancer in women globally and the 2nd most common in India. In India, between 2018 and 2020, cervical cancer saw a surge of 26,985 from 2018 to 2020. The treatment for cervical cancer depends on the clinical stage. Treatment of early stage cervical cancer (Stage IB1-IIA) includes chemo-radiation or surgery +\u002F- adjuvant (CT)RT and VBT if indicated. The choice of adjuvant treatment relies on identifying specific risk factors. Patients fulfilling Sedli's intermediate-risk criteria, requires pelvic radiotherapy alone and patients with high-risk Peter's criteria, require adjuvant chemoradiation. This risk-based approach helps tailor adjuvant therapies to individual patient.\n\nIndia reported 16,413 new cases and 6,385 deaths of endometrial cancer, with a mortality rate of 0.73%. The primary treatment for endometrial carcinoma is total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO). The Adjuvant treatment depends on risk stratification group according to ESGO\u002FESTRO\u002FESP guidelines determined through molecular-based risk stratification. Adjuvant treatment includes radiotherapy, chemotherapy, and brachytherapy.\n\nTo reduce the burden of acute and late toxicity, advanced external radiation techniques like image guided intensity modulated radiotherapy (IG IMRT) are used. IG IMRT have shown their potential to reduce late toxicity in long term survivors compared to 3DCRT technique. Since January 2020, our institution (TATA memorial centre, Mumbai) has incorporated routine IG-IMRT (Image-Guided Intensity-Modulated Radiation Therapy) for treatment of cervical and endometrial cancer. However, no post-implementation assessment of treatment outcomes and potential toxicity has occurred. This is retrospective observational study aims to evaluate the clinical application of IG-IMRT.\n\nPrimary aim of this study is to audit the 3 years incidence of ≥ grade II Gastrointestinal \\& Genitourinary toxicities in women receiving Adjuvant IMRT (with or without chemotherapy) between January 2020 to June 2023",[56,57],"Endometrial Cancer","Cervix Cancer",[59],"Cervical Cancer, Endometrical Cancer ,Gastrointestinal & Genitourinary toxicities","2026-02-26",{"date":62,"type":63},"2026-03-02","ACTUAL",{"date":65,"type":63},"2025-05-10",{"date":67,"type":52},"2026-08-25",{"name":5,"class":6},1]